🚀 VC round data is live in beta, check it out!
Aker BioMarine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aker BioMarine and similar public comparables like Kri-Kri Milk Industry, Seneca Foods, AG Barr, John B. Sanfilippo & Son and more.
Aker BioMarine Overview
About Aker BioMarine
Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include Human Health Ingredients, Consumer Health Ingredients, and Emerging Businesses. The company generates the majority of its revenue from the Human Health Ingredients segment, which includes Superba, Lysoveta, PL+ Algae, and the company's Houston manufacturing plant. The segment sells B2B krill oil supplements to nutritional brands for humans around the world.
Founded
2006
HQ
Employees
255
Website
Sectors
Financials (LTM)
EV
$1B
Aker BioMarine Financials
Aker BioMarine reported last 12-month revenue of $226M and EBITDA of $48M.
In the same LTM period, Aker BioMarine generated $104M in gross profit, $48M in EBITDA, and $4M in net income.
Revenue (LTM)
Aker BioMarine P&L
In the most recent fiscal year, Aker BioMarine reported revenue of $218M and EBITDA of $33M.
Aker BioMarine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $226M | XXX | $218M | XXX | XXX | XXX |
| Gross Profit | $104M | XXX | $98M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $48M | XXX | $33M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $4M | XXX | ($23M) | XXX | XXX | XXX |
| Net Margin | 2% | XXX | (10%) | XXX | XXX | XXX |
| Net Debt | — | — | $163M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aker BioMarine Stock Performance
Aker BioMarine has current market cap of $945M, and enterprise value of $1B.
Market Cap Evolution
Aker BioMarine's stock price is $10.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $945M | 2.0% | XXX | XXX | XXX | $-0.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAker BioMarine Valuation Multiples
Aker BioMarine trades at 4.9x EV/Revenue multiple, and 23.1x EV/EBITDA.
EV / Revenue (LTM)
Aker BioMarine Financial Valuation Multiples
As of May 1, 2026, Aker BioMarine has market cap of $945M and EV of $1B.
Equity research analysts estimate Aker BioMarine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aker BioMarine has a P/E ratio of 212.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $945M | XXX | $945M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 23.1x | XXX | 33.9x | XXX | XXX | XXX |
| EV/EBIT | 48.0x | XXX | 86.1x | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | 11.4x | XXX | XXX | XXX |
| P/E | 212.3x | XXX | (41.4x) | XXX | XXX | XXX |
| EV/FCF | 177.2x | XXX | (226.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aker BioMarine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aker BioMarine Margins & Growth Rates
Aker BioMarine's revenue in the last 12 month grew by 11%.
Aker BioMarine's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.3M for the same period.
Aker BioMarine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | (8%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aker BioMarine Public Comps
See public comps and valuation multiples for other Food & Beverages comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aker BioMarine | XXX | XXX | XXX | XXX | XXX | XXX |
| Kri-Kri Milk Industry | XXX | XXX | XXX | XXX | XXX | XXX |
| Seneca Foods | XXX | XXX | XXX | XXX | XXX | XXX |
| AG Barr | XXX | XXX | XXX | XXX | XXX | XXX |
| John B. Sanfilippo & Son | XXX | XXX | XXX | XXX | XXX | XXX |
| Mission Produce | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aker BioMarine M&A Activity
Aker BioMarine acquired XXX companies to date.
Last acquisition by Aker BioMarine was on XXXXXXXX, XXXXX. Aker BioMarine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aker BioMarine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAker BioMarine Investment Activity
Aker BioMarine invested in XXX companies to date.
Aker BioMarine made its latest investment on XXXXXXXX, XXXXX. Aker BioMarine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aker BioMarine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aker BioMarine
| When was Aker BioMarine founded? | Aker BioMarine was founded in 2006. |
| Where is Aker BioMarine headquartered? | Aker BioMarine is headquartered in Norway. |
| How many employees does Aker BioMarine have? | As of today, Aker BioMarine has over 255 employees. |
| Is Aker BioMarine publicly listed? | Yes, Aker BioMarine is a public company listed on Oslo Børs. |
| What is the stock symbol of Aker BioMarine? | Aker BioMarine trades under AKBM ticker. |
| When did Aker BioMarine go public? | Aker BioMarine went public in 2020. |
| Who are competitors of Aker BioMarine? | Aker BioMarine main competitors are Kri-Kri Milk Industry, Seneca Foods, AG Barr, John B. Sanfilippo & Son. |
| What is the current market cap of Aker BioMarine? | Aker BioMarine's current market cap is $945M. |
| What is the current revenue of Aker BioMarine? | Aker BioMarine's last 12 months revenue is $226M. |
| What is the current revenue growth of Aker BioMarine? | Aker BioMarine revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Aker BioMarine? | Current revenue multiple of Aker BioMarine is 4.9x. |
| Is Aker BioMarine profitable? | Yes, Aker BioMarine is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aker BioMarine? | Aker BioMarine's last 12 months EBITDA is $48M. |
| What is Aker BioMarine's EBITDA margin? | Aker BioMarine's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Aker BioMarine? | Current EBITDA multiple of Aker BioMarine is 23.1x. |
| What is the current FCF of Aker BioMarine? | Aker BioMarine's last 12 months FCF is $6M. |
| What is Aker BioMarine's FCF margin? | Aker BioMarine's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Aker BioMarine? | Current FCF multiple of Aker BioMarine is 177.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.